{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:40:15Z","timestamp":1740166815472,"version":"3.37.3"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oral antimicrobials remain the mainstay of long-term treatment for many infections. Meanwhile, the use of oral agents is becoming commonplace for the treatment of several pediatric infections once managed exclusively with parenteral therapies. Unfortunately, antimicrobials are associated with several laboratory toxicities, particularly when high doses or combination therapies are used, but there is a paucity of data on optimal laboratory monitoring strategies. In this ID Consultant article, we offer a summary of the 3 most common laboratory-based toxicities seen with long-term use of oral antimicrobials\u2014drug-induced kidney injury, liver injury, and hematological toxicities\u2014and we provide our recommended approach to monitoring.<\/jats:p>","DOI":"10.1093\/jpids\/piae091","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T06:17:21Z","timestamp":1725344241000},"page":"551-560","source":"Crossref","is-referenced-by-count":0,"title":["ID Consultant: Laboratory Monitoring During Long-Term Use of Oral Antimicrobials in Pediatric Patients"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-8146","authenticated-orcid":false,"given":"Kevin J","family":"Downes","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania ,","place":["USA"]},{"name":"Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinsae","family":"Alemayehu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Adolescent Health, University of Botswana , Gaborone ,","place":["Botswana"]},{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics and Child Health, St. Paul\u2019s Hospital Millennium Medical College , Addis Ababa ,","place":["Ethiopia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-4770","authenticated-orcid":false,"given":"Liat","family":"Ashkenazi-Hoffnung","sequence":"additional","affiliation":[{"name":"Department of Day Hospitalization, Schneider Children\u2019s Medical Center of Israel , Petah Tikva ,","place":["Israel"]},{"name":"Faculty of Medicine and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"2024110417165452100_CIT0001","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.2018.5690","article-title":"Trends in prescription medication use among children and adolescents\u2014United States, 1999\u20132014","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"key":"2024110417165452100_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkz325","article-title":"Mechanisms of antimicrobial-induced nephrotoxicity in children","volume":"75","author":"Downes","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024110417165452100_CIT0003","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.ekir.2023.08.031","article-title":"Overview of antibiotic-induced nephrotoxicity","volume":"8","author":"Campbell","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2024110417165452100_CIT0004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1542\/hpeds.2015-0069","article-title":"Adverse events in pediatric patients receiving long-term oral and intravenous antibiotics","volume":"6","author":"Murphy","year":"2016","journal-title":"Hosp Pediatr"},{"key":"2024110417165452100_CIT0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/adc.2010.208843","article-title":"Ciprofloxacin safety in paediatrics: a systematic review","volume":"96","author":"Adefurin","year":"2011","journal-title":"Arch Dis Child"},{"key":"2024110417165452100_CIT0006","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024110417165452100_CIT0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.ackd.2019.08.001","article-title":"Nephrotoxicity of antimicrobials and antibiotics","volume":"27","author":"Morales-Alvarez","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"2024110417165452100_CIT0008","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4103\/ijn.IJN_295_18","article-title":"A rare case of acute kidney injury due to levofloxacin-induced crystal nephropathy","volume":"29","author":"Ansari","year":"2019","journal-title":"Indian J Nephrol"},{"key":"2024110417165452100_CIT0009","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/archderm.1976.01630350071017","article-title":"Safety of long-term tetracycline therapy for acne","volume":"112","author":"Sauer","year":"1976","journal-title":"Arch Dermatol"},{"key":"2024110417165452100_CIT0010","first-page":"492","article-title":"Prospective study on the safety of long-term tetracycline therapy for acne","volume":"27","author":"Sauer","year":"1981","journal-title":"Cutis"},{"key":"2024110417165452100_CIT0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/archderm.1976.01630280009002","article-title":"High-dose tetracycline therapy in severe acne","volume":"112","author":"Baer","year":"1976","journal-title":"Arch Dermatol"},{"key":"2024110417165452100_CIT0012","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archderm.1982.01650240033017","article-title":"Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris","volume":"118","author":"Hubbell","year":"1982","journal-title":"Arch Dermatol"},{"key":"2024110417165452100_CIT0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jpids\/piu037","article-title":"Adverse events in pediatric patients receiving long-term outpatient antimicrobials","volume":"4","author":"Olson","year":"2015","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2024110417165452100_CIT0014","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.ekir.2020.04.008","article-title":"Time to acute kidney injury in \u03b2-lactam-induced acute interstitial nephritis","volume":"5","author":"Lazarus","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2024110417165452100_CIT0015","doi-asserted-by":"crossref","first-page":"c187","DOI":"10.1159\/000328911","article-title":"Trimethoprim, creatinine and creatinine-based equations","volume":"119","author":"Delanaye","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"2024110417165452100_CIT0016","first-page":"663","article-title":"Renal impairment associated with trimethoprim-sulfamethoxazole use in the pediatric population","volume":"27","author":"Sierra","year":"2022","journal-title":"JPPT"},{"key":"2024110417165452100_CIT0017","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/uog.23685","article-title":"Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy","volume":"58","author":"Faure-Bardon","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2024110417165452100_CIT0018","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/TP.0000000000002632","article-title":"Efficacy and safety of a weight-based dosing regimen of valganciclovir for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients","volume":"103","author":"Pappo","year":"2019","journal-title":"Transplantation"},{"key":"2024110417165452100_CIT0019","doi-asserted-by":"crossref","first-page":"e12833","DOI":"10.1111\/petr.12833","article-title":"Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and\/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease","volume":"21","author":"Varela-Fascinetto","year":"2017","journal-title":"Pediatr Transplant"},{"key":"2024110417165452100_CIT0020","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1111\/ajt.17171","article-title":"Antiviral toxicities in pediatric solid organ transplant recipients","volume":"22","author":"Hayes","year":"2022","journal-title":"Am J Transplant"},{"key":"2024110417165452100_CIT0021","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ekir.2018.11.014","article-title":"Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy","volume":"4","author":"Soto","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2024110417165452100_CIT0022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.ackd.2018.12.001","article-title":"The changing face of human immunodeficiency virus-mediated kidney disease","volume":"26","author":"Sury","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"2024110417165452100_CIT0023","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.ajkd.2017.02.376","article-title":"Atazanavir-associated crystalline nephropathy","volume":"70","author":"Santoriello","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2024110417165452100_CIT0024","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study","volume":"207","author":"Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"2024110417165452100_CIT0025","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/ndt\/gft210","article-title":"The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients","volume":"28","author":"Wikman","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2024110417165452100_CIT0026","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years","volume":"21","author":"Nelson","year":"2007","journal-title":"AIDS"},{"key":"2024110417165452100_CIT0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects","volume":"62","author":"Wong","year":"2015","journal-title":"Hepatology (Baltimore Md.)"},{"key":"2024110417165452100_CIT0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf"},{"key":"2024110417165452100_CIT0029","doi-asserted-by":"crossref","first-page":"e28096","DOI":"10.1371\/journal.pone.0028096","article-title":"Development and inter-rater reliability of the liverpool adverse drug reaction causality assessment tool","volume":"6","author":"Gallagher","year":"2011","journal-title":"PLoS One"},{"key":"2024110417165452100_CIT0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/pds.1547","article-title":"Adverse events associated with prolonged antibiotic use","volume":"17","author":"Meropol","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"author":"Woosley","key":"2024110417165452100_CIT0031"},{"key":"2024110417165452100_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 infectious diseases society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024110417165452100_CIT0033","doi-asserted-by":"crossref","first-page":"e3572","DOI":"10.1093\/cid\/ciaa1391","article-title":"Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024110417165452100_CIT0034","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.ki.5000032","article-title":"3\u20135 year longitudinal follow-up of pediatric patients after acute renal failure","volume":"69","author":"Askenazi","year":"2006","journal-title":"Kidney Int"},{"key":"2024110417165452100_CIT0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MOP.0000000000001202","article-title":"Long-term outcomes of acute kidney injury in children","volume":"35","author":"Schuermans","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"2024110417165452100_CIT0036","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2215\/CJN.04240415","article-title":"Follow-Up Renal Assessment of Injury Long-Term After Acute Kidney Injury (FRAIL-AKI)","volume":"11","author":"Cooper","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024110417165452100_CIT0037","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024110417165452100_CIT0038","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2215\/CJN.12001018","article-title":"Treatment of drug-induced acute tubulointerstitial nephritis: the search for better evidence","volume":"13","author":"Moledina","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024110417165452100_CIT0039","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonz\u00e1lez","year":"2008","journal-title":"Kidney Int"},{"key":"2024110417165452100_CIT0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","article-title":"Crystal-induced acute renal failure","volume":"106","author":"Perazella","year":"1999","journal-title":"Am J Med"},{"key":"2024110417165452100_CIT0041","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.ekir.2021.09.003","article-title":"The crystalline nephropathies","volume":"6","author":"Perazella","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024110417165452100_CIT0042","doi-asserted-by":"crossref","first-page":"891336","DOI":"10.3389\/fphar.2022.891336","article-title":"Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024110417165452100_CIT0043","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/9781119251316.ch28","article-title":"Mechanisms of drug-induced liver injury","volume-title":"Schiff\u2019s Diseases of the Liver","author":"Watkins","year":"2017"},{"key":"2024110417165452100_CIT0044","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/jps.23584","article-title":"An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters","volume":"102","author":"Yang","year":"2013","journal-title":"J Pharm Sci"},{"key":"2024110417165452100_CIT0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12879-017-2330-z","article-title":"Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK","volume":"17","author":"Abbara","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2024110417165452100_CIT0046","doi-asserted-by":"crossref","first-page":"dlz026","DOI":"10.1093\/jacamr\/dlz026","article-title":"Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK","volume":"1","author":"Chapman","year":"2019","journal-title":"JAC Antimicrob Resist"},{"key":"2024110417165452100_CIT0047","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Hepatology"},{"author":"US Food and Drug Administration","key":"2024110417165452100_CIT0048","article-title":"Drug Induced Liver Injury rank (DILIrank) Dataset"},{"year":"2012","author":"Ciprofloxacin","key":"2024110417165452100_CIT0049"},{"key":"2024110417165452100_CIT0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2024110417165452100_CIT0051","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cld.2007.06.009","article-title":"Hepatotoxicity due to antibiotics","volume":"11","author":"Polson","year":"2007","journal-title":"Clin Liver Dis"},{"key":"2024110417165452100_CIT0052","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biomedicines11010015","article-title":"Treatment of drug-induced liver injury","volume":"11","author":"Teschke","year":"2023","journal-title":"Biomedicines"},{"volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012","key":"2024110417165452100_CIT0053"},{"key":"2024110417165452100_CIT0054","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1586\/17474124.2016.1127756","article-title":"Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review","volume":"10","author":"Stine","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2024110417165452100_CIT0055","doi-asserted-by":"crossref","first-page":"e1987","DOI":"10.1002\/mgg3.1987","article-title":"NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients","volume":"10","author":"Jaramillo-Valverde","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"2024110417165452100_CIT0056","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ueg2.12113","article-title":"Clinical management of patients with drug-induced liver injury (DILI)","volume":"9","author":"Bj\u00f6rnsson","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2024110417165452100_CIT0057","doi-asserted-by":"crossref","first-page":"49","DOI":"10.20473\/jr.v6-I.2.2020.49-54","article-title":"Tuberculosis drug-induced liver injury","volume":"6","author":"Soedarsono","year":"2020","journal-title":"Jurnal Respirasi"},{"key":"2024110417165452100_CIT0058","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","author":"Andrade","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2024110417165452100_CIT0059","first-page":"e920350","article-title":"Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study","volume":"26","author":"Zhao","year":"2020","journal-title":"Med Sci Monit"},{"key":"2024110417165452100_CIT0060","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/jcm8091351","article-title":"State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies","volume":"8","author":"Andr\u00e8s","year":"2019","journal-title":"J Clin Med"},{"key":"2024110417165452100_CIT0061","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1060028020975646","article-title":"A review of \u03b2-lactam-associated neutropenia and implications for cross-reactivity","volume":"55","author":"Cimino","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2024110417165452100_CIT0062","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ajt.2023.07.013","article-title":"Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients","volume":"23","author":"Demirhan","year":"2023","journal-title":"Am J Transplant"},{"key":"2024110417165452100_CIT0063","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/INF.0000000000002079","article-title":"Hematologic adverse events associated with prolonged valganciclovir treatment in congenital cytomegalovirus infection","volume":"38","author":"Ziv","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2024110417165452100_CIT0064","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jiac.2024.03.006","article-title":"Assessment of patients\u2019 characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease","volume":"30","author":"Kakei","year":"2024","journal-title":"J Infect Chemother"},{"key":"2024110417165452100_CIT0065","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000001561","article-title":"High frequency of bone marrow depression during congenital toxoplasmosis therapy in a cohort of children identified by neonatal screening in Minas Gerais, Brazil","volume":"36","author":"Carellos","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2024110417165452100_CIT0066","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2010-03-276691","article-title":"Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods","volume":"116","author":"Reese","year":"2010","journal-title":"Blood"},{"key":"2024110417165452100_CIT0067","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jiac.2021.03.003","article-title":"A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for Gram-positive bacterial infections","volume":"27","author":"Kato","year":"2021","journal-title":"J Infect Chemother"},{"key":"2024110417165452100_CIT0068","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/10600280231189897","article-title":"A real-world disproportionality analysis of drug-induced immune hemolytic anemia in the FDA adverse event reporting system","volume":"58","author":"Tang","year":"2024","journal-title":"Ann Pharmacother"},{"key":"2024110417165452100_CIT0069","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","article-title":"Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review","volume":"33","author":"Youngster","year":"2010","journal-title":"Drug Saf"},{"key":"2024110417165452100_CIT0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4269\/ajtmh.23-0280","article-title":"Severe hemolysis during primaquine radical cure of plasmodium vivax malaria: two systematic reviews and individual patient data descriptive analyses","volume":"109","author":"Yilma","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"2024110417165452100_CIT0071","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02751889","article-title":"Surveillance of drug induced diseases in children","volume":"61","author":"Kushwaha","year":"1994","journal-title":"Indian J Pediatr"},{"key":"2024110417165452100_CIT0072","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/TCRM.S325742","article-title":"The relationship of drug therapy to aplastic anemia in Pakistan: a hospital-based case control study","volume":"17","author":"Syed","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"2024110417165452100_CIT0073","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/ehm.11.12","article-title":"Clinical presentation and management of drug-induced agranulocytosis","volume":"4","author":"Andr\u00e8s","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"2024110417165452100_CIT0074","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"key":"2024110417165452100_CIT0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2020006479","article-title":"Anemia in the pediatric patient","volume":"140","author":"Gallagher","year":"2022","journal-title":"Blood"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piae091\/59000233\/piae091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/10\/551\/60414915\/piae091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/10\/551\/60414915\/piae091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:17:16Z","timestamp":1730740636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/13\/10\/551\/7748041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piae091","relation":{},"ISSN":["2048-7207"],"issn-type":[{"type":"electronic","value":"2048-7207"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,3]]}}}